Day 5 Recap: AAD 2025

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

JNJ-2113 and vilobelimab show promise in treating plaque psoriasis and pyoderma gangrenosum, with strong safety profiles.
Lebrikizumab demonstrates sustained efficacy in atopic dermatitis, achieving significant skin clearance over three years.
Energy-based devices are increasingly important in acne treatment, as highlighted in recent discussions.
Alumis's ESK-001 shows positive clinical response and safety in plaque psoriasis after 52 weeks of treatment.
Ongoing benzoyl peroxide and benzene research updates are being interpreted as clinicians await regulatory guidance.

Catch up on coverage from the final day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Icotrokinra Demonstrates Promise in Phase 3 ICONIC-LEAD and ICONIC-ADVANCE for Plaque Psoriasis

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Lebrikizumab Shows 3-Year Sustained Efficacy in AD

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Michael Gold, MD: Advances in Acne Treatment and Energy-Based Devices

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

Late-Breaking ESK-001 Data from the OLE STRIDE Trial Presented at AAD 2025

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

Click here for all content from AAD 2025.